ADXN Stock: Price, Forecast, Financials & AI Analysis

Loading...

High

8.330

Open

8.110

VWAP

7.90

Vol

4.47K

Mkt Cap

10.26M

Low

7.580

Amount

35.35K

EV/EBITDA(TTM)

--

Total Shares

1.23M

EV

9.87M

EV/OCF(TTM)

--

P/S(TTM)

35.55

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

Show More

Events Timeline

(ET)

2026-01-13

12:20:00

Addex Therapeutics Ltd - ADR Trading Halted Due to Volatility Trading Pause

2026-01-07 (ET)

2026-01-07

05:10:00

Addex Therapeutics' Spin-Out Neurosterix Starts Phase 1 Study of NTX-253

2025-06-06 (ET)

2025-06-06

05:06:10

Addex reports anti-tussive activity of GABAB positive allosteric modulator

2025-04-30 (ET)

2025-04-30

05:39:19

Addex Therapeutics enters collaboration with Sinntaxis AB

2025-04-17 (ET)

2025-04-17

05:21:07

Addex Therapeutics regains rights to ADX71149

2024-09-30 (ET)

2024-09-30

05:26:09

Addex Therapeutics reports Q2 EPS CHF 0.08 vs. (CHF 0.04) last year

News

an image of Globenewswire

01-07Globenewswire

Addex's Spin-Out Neurosterix Initiates Phase 1 Study of NTX-253 for Schizophrenia

an image of Globenewswire

2025-12-11Globenewswire

Addex Amends $3.3 Million At-The-Market Offering Agreement

an image of Newsfilter

2025-12-11Newsfilter

Addex Amends ATM Agreement with H.C. Wainwright for $3.3M Offering

an image of Benzinga

2025-12-04Benzinga

UiPath Shares Rise Approximately 9%; Check Out 20 Stocks Making Moves in Premarket Trading

an image of Globenewswire

2025-12-04Globenewswire

Addex Reports Q3 2025 Financial Results with CHF 1.58M Net Loss

an image of Globenewswire

2025-12-01Globenewswire

Addex Therapeutics to Report Q3 2025 Financial Results on December 4

Valuation Metrics

The current forward P/E ratio for Addex Therapeutics Ltd (ADXN.O) is 0.00, compared to its 5-year average forward P/E of -1.36. For a more detailed relative valuation and DCF analysis to assess Addex Therapeutics Ltd 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-1.36

Current PE

0.00

Overvalued PE

-0.17

Undervalued PE

-2.56

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-0.99

Current EV/EBITDA

-1.36

Overvalued EV/EBITDA

-0.20

Undervalued EV/EBITDA

-1.78

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PS

17.01

Current PS

4.31

Overvalued PS

39.71

Undervalued PS

-5.69

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Addex Therapeutics Ltd (ADXN) stock price today?

The current price of ADXN is 8.33 USD — it has increased 2.84 % in the last trading day.

What is Addex Therapeutics Ltd (ADXN)'s business?

Addex Therapeutics Ltd is a Switzerland-based clinical-stage pharmaceutical company. The Company focuses on development and commercialization of orally available small molecule drugs known as allosteric modulators for neurological disorders. The Company’s clinical programs pipeline include dipraglurant (mGlu5 NAM), which is Phase 2a placebo-controlled clinical trial for Parkinson's disease levodopa-induced dyskinesia (PD-LID), and is being prepared to enter registration trials for PD-LID, and ADX71149 (mGlu2 positive allosteric modulator or PAM), which is being developed in collaboration by its partner Janssen Pharmaceuticals, Inc to treat schizophrenia and anxious depression. It also is advancing several preclinical programs, including GABABPAM for pain, overactive bladder and other disorders, mGlu7 NAM for post-traumatic stress disorder, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders.

What is the price predicton of ADXN Stock?

Wall Street analysts forecast ADXN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for ADXN is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Addex Therapeutics Ltd (ADXN)'s revenue for the last quarter?

Addex Therapeutics Ltd revenue for the last quarter amounts to 62.01K USD, decreased -7.97 % YoY.

What is Addex Therapeutics Ltd (ADXN)'s earnings per share (EPS) for the last quarter?

Addex Therapeutics Ltd. EPS for the last quarter amounts to -0.02 USD, decreased -0.00 % YoY.

How many employees does Addex Therapeutics Ltd (ADXN). have?

Addex Therapeutics Ltd (ADXN) has 2 emplpoyees as of January 17 2026.

What is Addex Therapeutics Ltd (ADXN) market cap?

Today ADXN has the market capitalization of 10.26M USD.